Allogeneic Cardiosphere-derived Cells for the Treatment of Heart Failure with Reduced Ejection Fraction: Results of the Dilated cardiomYopathy iNtervention with Allogeneic Myocardially-regeneratIve Cells (DYNAMIC) trial.

CONCLUSIONS: Global intracoronary infusion of allogeneic CDCs is safe and feasible. The efficacy of allogeneic CDCs in HFrEF needs to be tested in larger randomized trials. PMID: 31763984 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31763984?dopt=Abstract

Source: EuroIntervention - November 27, 2019 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research